Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

View All Documentation

L9787

Sigma-Aldrich

L-655,708

≥98% (HPLC), powder

Synonym(e):

Ethyl (S)-11,12,13,13a-Tetrahydro-7-methoxy-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate, L-655708

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C18H19N3O4
CAS-Nummer:
130477-52-0
Molekulargewicht:
341.36
MDL-Nummer:
MFCD02684528
UNSPSC-Code:
12352200
PubChem Substanz-ID:
24278527
NACRES:
NA.77

Assay

≥98% (HPLC)

Form

powder

Löslichkeit

DMSO: ≥6.0 mg/mL (Warmed)
H2O: insoluble

Ersteller

Merck & Co., Inc., Kenilworth, NJ, U.S.

SMILES String

CCOC(=O)c1ncn2-c3ccc(OC)cc3C(=O)N4CCCC4c12

InChI

1S/C18H19N3O4/c1-3-25-18(23)15-16-14-5-4-8-20(14)17(22)12-9-11(24-2)6-7-13(12)21(16)10-19-15/h6-7,9-10,14H,3-5,8H2,1-2H3/t14-/m0/s1

InChIKey

YKYOQIXTECBVBB-AWEZNQCLSA-N

Angaben zum Gen

human ... GABRA5(2558)

Anwendung

L-655,708 has been used as an α5 GABAA receptor inverse agonist to inhibit the discriminative stimulus of propofol in a dose-dependent manner.

Biochem./physiol. Wirkung

L-655,708 is an inverse agonist of the α5 γ-Aminobutyric acid type A (GABAA) receptor. It has an ability to increase cognition in rats.
Novel ligand selective for the benzodiazepine site of GABAA receptors which contain the α5 subunit.

Leistungsmerkmale und Vorteile

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves, type N95 (US)

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Flavia R Carreno et al.
The international journal of neuropsychopharmacology, 20(6), 504-509 (2017-03-25)
Selective augmentation of hippocampal activity in ways similar to that caused by ketamine may have therapeutic advantages over ketamine, which has psychotomimetic and reinforcing effects likely due to effects outside the hippocampus (i.e., off-target effects). Here we evaluated the antidepressant-like
C Sur et al.
Molecular pharmacology, 54(5), 928-933 (1998-11-06)
The gamma-aminobutyric acid (GABA)A receptor is a hetero-oligomer consisting of five subunits, the combination of which confers unique pharmacological properties to the receptor. To understand the physiological role of native GABAA receptors, it is critical to determine their subunit compositions.
L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors
Atack JR, et al.
Neuropharmacology, 51(6), 1023-1029 (2006)
M Xue et al.
European journal of pain (London, England), 21(6), 1061-1071 (2017-02-02)
γ-Aminobutyric acid (GABA) type A receptors (GABA The C fibre-evoked field potentials were recorded in superficial dorsal horn of spinal cord, and the effects of α5-GABA Inhibition of α5-GABA α5-GABA Tonic inhibition generated by α5-GABA
Jonathan Fischell et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(11), 2499-2509 (2015-04-23)
Selective serotonin reuptake inhibitors (SSRIs) are the primary pharmacological treatment for depression, but SSRIs are effective in only half of the patients and typically take several weeks to relieve symptoms. The NMDA receptor antagonist ketamine exerts a rapid antidepressant action
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.